Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) greatly improve the survival and quality of life of non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, many patients exhibit de novo or primary/early resistance. In addition, patients who initially respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yijia, Song, Jun, Wang, Yanru, Huang, Letian, Sun, Li, Zhao, Jianzhu, Zhang, Shuling, Jing, Wei, Ma, Jietao, Han, Chengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758444/
https://www.ncbi.nlm.nih.gov/pubmed/33363040
http://dx.doi.org/10.3389/fonc.2020.610923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758444/
https://www.ncbi.nlm.nih.gov/pubmed/33363040
http://dx.doi.org/10.3389/fonc.2020.610923

Ejemplares similares